Art. -Nr.: HY-N2112

Glaucocalyxin A

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 79498-31-0
Formel: C₂₀H₂₈O₄
Molecular Weight:332.43

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Glaucocalyxin A Chemical Structure

CAS. Nr.: 79498-31-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

PI3K

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.39 μM Compound: 18	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 19425589]
A549	IC₅₀	7.5 μM Compound: GLA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25164762]
B16	IC₅₀	4.84 μM Compound: GLA	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 25164762]
HL-60	IC₅₀	5.52 μM Compound: GLA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25164762]
KB	IC₅₀	6.47 μM Compound: GLA	Antiproliferative activity against human KB cells after 48 hrs by MTT assay Antiproliferative activity against human KB cells after 48 hrs by MTT assay	[PMID: 25164762]
L02	IC₅₀	8.62 μM Compound: GLA	Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 25164762]
MCF7	IC₅₀	8.73 μM Compound: 18	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 19425589]
NB-4	IC₅₀	2.9 μM Compound: 18	Cytotoxicity against human NB4 cells after 48 hrs by SRB method Cytotoxicity against human NB4 cells after 48 hrs by SRB method	[PMID: 19425589]
PC-3	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human PC3 cells after 48 hrs by SRB method Cytotoxicity against human PC3 cells after 48 hrs by SRB method	[PMID: 19425589]
Platelet	IC₅₀	13.7 μM Compound: GLA	Inhibition of PAF-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by PAF stimulation by turbidimetric method Inhibition of PAF-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by PAF stimulation by turbidimetric method	[PMID: 32463237]
Platelet	IC₅₀	14.1 μM Compound: GLA	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by AA stimulation by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by AA stimulation by turbidimetric method	[PMID: 32463237]
Platelet	IC₅₀	4.4 μM Compound: GLA	Inhibition of ADP-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by ADP stimulation by turbidimetric method Inhibition of ADP-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by ADP stimulation by turbidimetric method	[PMID: 32463237]
SGC-7901	IC₅₀	11.7 μM Compound: GLA	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 25164762]
SH-SY5Y	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method	[PMID: 19425589]
SMMC-7721	IC₅₀	8.11 μM Compound: GLA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25164762]

In Vitro

Glaucocalyxin A induces apoptosis by mitochondrial apoptotic pathway through several steps including increasing the Bax/Bcl-2 ratio, triggering the intracellular reactive oxygen species (ROS) generation, reducing mitochondrial membrane potential (MMP), and inducing cleavage of caspase-9 and caspase-3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 79498-31-0
Appearance Solid
Molecular Weight 332.43
Formel C₂₀H₂₈O₄
Color White to off-white
SMILES

CC1(C)C(CC[C@@]2(C)[C@@]3([H])[C@@]4(C(C([C@H](CC3)[C@H]4O)=C)=O)[C@H](O)C[C@]12[H])=O
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Labiatae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Phytomedicine

Glaucocalyxin a protect liver function via inhibiting platelet over-activation during sepsis. [Abstract]

2022 Jun;100:154089. PMID: 35398736
Int J Mol Sci

Glaucocalyxin A Ameliorates Hypoxia/Reoxygenation-Induced Injury in Human Renal Proximal Tubular Epithelial Cell Line HK-2 Cells. [Abstract]

2021 Dec 31;23(1):446. PMID: 35008870

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (150.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0082 mL

15.0408 mL

30.0815 mL

5 mM

0.6016 mL

3.0082 mL

6.0163 mL

10 mM

0.3008 mL

1.5041 mL

3.0082 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu J, et al. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nucleartranslocation via regulating PI3K/Akt pathway. Cell Death Dis. 2018 Jun 13;9(6):708. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0082 mL	15.0408 mL	30.0815 mL	75.2038 mL
	5 mM	0.6016 mL	3.0082 mL	6.0163 mL	15.0408 mL
	10 mM	0.3008 mL	1.5041 mL	3.0082 mL	7.5204 mL
	15 mM	0.2005 mL	1.0027 mL	2.0054 mL	5.0136 mL
	20 mM	0.1504 mL	0.7520 mL	1.5041 mL	3.7602 mL
	25 mM	0.1203 mL	0.6016 mL	1.2033 mL	3.0082 mL
	30 mM	0.1003 mL	0.5014 mL	1.0027 mL	2.5068 mL
	40 mM	0.0752 mL	0.3760 mL	0.7520 mL	1.8801 mL
	50 mM	0.0602 mL	0.3008 mL	0.6016 mL	1.5041 mL
	60 mM	0.0501 mL	0.2507 mL	0.5014 mL	1.2534 mL
	80 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9400 mL
	100 mM	0.0301 mL	0.1504 mL	0.3008 mL	0.7520 mL

Keywords

Glaucocalyxin A

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Glaucocalyxin A

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Glaucocalyxin A

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Glaucocalyxin A Related Classifications

HY-N2112 Related Classifications